Why the study?
The study was conducted to determine the impact of genetic and nongenetic factors on treatment outcomes in patients receiving dual antiplatelet therapy after PCI and stent implantation.
Key points are not available for this paper at this time.
Population
628 patients receiving dual antiplatelet therapy after PCI and stent implantation
Comparison
Genetic (CYP2C19 and CYP4F2 variants) and nongenetic factors in clopidogrel vs ticagrelor users
May warrant aspirin caution in CYP4F2 T carriers on clopidogrel post-PCI; leaves open genotype-guided DAPT trials.
Aim: The aim of this study was to determine the impact of genetic and nongenetic factors on treatment outcomes in patients receiving dual antiplatelet therapy after percutaneous coronary intervention and stent implantation. Materials & methods: Patients (n = 628) used clopidogrel or ticagrelor for at least 1 week before platelet aggregation test. Results: Multivariate binary regression analysis demonstrated that aspirin use and CYP4F2 T allele significantly increased odds for bleeding in clopidogrel users (OR: 2.488, 95% CI: 1.452–4.265; p = 0.001 and OR: 1.573, 95% CI: 1.066–2.320; respectively; p = 0.022). CYP4F2 T allele significantly increased odds for bleeding in ticagrelor users (OR: 8.270, 95% CI: 3.917–17.462; p < 0.001). Conclusion: Aspirin use and CYP4F2 T allele were significantly associated with bleeding during dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Tatarūnas et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: